NewLimit, the longevity biotech startup founded by Coinbase CEO Brian Armstrong, has raised $130 million in Series B funding. The round was led by Kleiner Perkins, with participation from new backers like Nat Friedman, Daniel Gross, and Khosla Ventures. Existing investors—including Founders Fund, Elad Gil, Garry Tan, and Patrick Collison—also returned to support the company’s mission.
The company’s goal is to slow or reverse aging by genetically reprogramming human cells. This latest funding brings NewLimit closer to developing treatments that help people live longer, healthier lives.
Co-founded by Armstrong, former GV partner Blake Byers, and stem cell scientist Jacob Kimmel, NewLimit is making steady progress. The company has developed three prototype drugs that appear to rejuvenate liver cells. These treated cells have shown a restored ability to process fat and alcohol—functions that often decline with age.
NewLimit measures progress by comparing how liver cells from young and old individuals react to substances. According to Kimmel, the reprogrammed older cells begin to behave more like their younger counterparts.
Although these results are promising, NewLimit is still years away from human trials. For now, the team is focused on speeding up discovery. They’re using an AI model to simulate experiments, select promising drug candidates, and refine the process using real-world lab data. This “lab-in-the-loop” method allows them to move faster while improving accuracy over time.
This round follows a $40 million Series A raised two years ago. Since then, the startup has advanced both its drug pipeline and its AI-driven approach to testing.
NewLimit joins a growing group of biotech startups aiming to extend human lifespan. Retro Biosciences, backed by OpenAI CEO Sam Altman, raised $180 million and is reportedly seeking $1 billion more. Meanwhile, Altos Labs launched in 2022 with $3 billion in funding, supported by Amazon founder Jeff Bezos.
As competition heats up, NewLimit’s focus on AI and cellular reprogramming sets it apart. If successful, their work could redefine how we age—and how long we live well.
